Patient characteristics of psoriatic arthritis patients with/without obesity (n=431)
| Non-obese (n=295) | Obese (n=136) | |
| Age, years | 51.5 (13.1) | 54.4 (11.0) * |
| Female, n (%) | 125 (43.3) | 84 (62.2) ** |
| Schooling, years | 12.5 (4.2) | 11.7 (4.6) |
| Duration of PsA, years | 11.1 (8.3) | 10.5 (7.8) |
| Number of other comorbidities (FCI), 0–17 | 1.6 (0.9) | 2.4 (2.0) ** |
| Current use of csDMARDs, n (%) | 170 (61.2) | 85 (66.9) |
| Current use of bDMARDs n (%) | 173 (61.3) | 76 (60.8) |
| Tender joints, 0–68 | 4.0 (8.4) | 6.5 (11.7) * |
| Swollen joints, 0–66 | 2.5 (8.4) | 1.7 (2.8) |
| Leeds enthesitis index, 0–6 | 0.5 (1.2) | 0.9 (1.7) ** |
| Psoriasis severity, n (%) | ||
| No psoriasis/ limited psoriasis (<1–5%) | 258 (91.8) | 116 (88.6) |
| Extensive psoriasis (6–20%) | 18 (6.4) | 13 (9.9) |
| Very extensive psoriasis (>20) | 5 (1.8) | 2 (1.5) |
| CRP, mg/dL | 1.2 (3.5) | 2.3 (8.1) * |
| Pain, 0–10 | 3.8 (2.7) | 4.8 (2.8) ** |
| PGA disease activity, 0–10 | 2.9 (2.5) | 3.5 (2.5) * |
| HAQ-DI, 0–3 | 0.5 (0.6) | 0.9 (0.7) ** |
| DAPSA | 15.2 (17.0) | 19.9 (18.0) * |
| PsAID-12, 0–10 | 3.0 (2.3) | 4.1 (2.6) ** |
| Pain, 0–10 | 3.7 (2.8) | 4.7 (2.8) ** |
| Skin, 0–10 | 2.5 (2.7) | 3.0 (2.9) |
| Fatigue, 0–10 | 3.9 (3.0) | 4.8 (3.2) ** |
| Work or leisure activities, 0–10 | 3.3 (3.0) | 4.8 (3.26) ** |
| Functional capacity, 0–10 | 3.3 (2.9) | 4.5 (3.2) ** |
| Discomfort, 0–10 | 3.4 (2.9) | 4.6 (3.0) ** |
| Sleep, 0–10 | 2.9 (3.1) | 4.1 (3.4) ** |
| Anxiety, 0–10 | 2.8 (3.0) | 3.5 (3.3) * |
| Coping, 0–10 | 2.5 (2.6) | 3.4 (3.0) ** |
| Embarrassment, 0–10 | 1.8 (2.7) | 2.8 (3.3) ** |
| Social participation, 0–10 | 2.1 (2.9) | 3.0 (3.3) ** |
| Depression, 0–10 | 1.9 (2.7) | 2.9 (3.3) ** |
Mean (SD) shown unless specified otherwise. *p<0.05; **p<0.01 for comparisons between non-obese and obese groups.
bDMARDs, biological disease modifying anti-rheumatic drugs; CRP, C reactive protein; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs; DAPSA, Disease Activity in PSoriatic Arthritis; FCI, Functional Comorbidity Index; HAQ-DI, Health Assessment Questionnaire Disability Index; LDA, low disease activity; PGA, patient global assessment of disease activity; PsA, psoriatic arthritis; PsAID, Psoriatic Arthritis Impact of Disease.